Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953849 · ClinicalTrials.gov registry record · Phase 1
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
A Phase 1 study of Mouth Neoplasms, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00953849: Completed Phase 1 study of Mouth Neoplasms, sponsored by VA Office of Research and Development.
NCT00953849 is a Phase 1 study of Mouth Neoplasms that has completed, run by VA Office of Research and Development. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00953849, a Phase 1 study of Mouth Neoplasms, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The poor survival of Veterans with oral cancer underscores the significance of identifying new treatment approaches. The proposed studies will test a new 2 pronged immunotherapeutic approach for oral cancer patients which lessen the immune inhibitory environment while maturing cells that can stimulate T cell reactivity against oral cancer cells.
Primary Outcome
Change in IL-2 stimulatory cytokine levels within tumor tissue.
Conditions Studied
Interventions
- DRUG Celecoxib
- DRUG Calcitriol
- DRUG Celecoxib plus Calcitriol
Study Locations (1)
South Carolina
- Ralph H. Johnson VA Medical Center, Charleston, SC - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT00953849 record still lists
NCT00953849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Mouth Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Celecoxib is the first listed.
NCT00953849 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT00953849 about?
NCT00953849 is a clinical study titled "Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity". The poor survival of Veterans with oral cancer underscores the significance of identifying new treatment approaches. The proposed studies will test a new 2 pronged immunotherapeutic approach for oral cancer patients which lessen the immune inhibitory environment while maturing cells that can stimula...
What is the current status of trial NCT00953849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2009-11. Estimated completion is 2015-12.
What conditions does trial NCT00953849 study?
This clinical trial studies the following conditions: Mouth Neoplasms.
What interventions are being tested in trial NCT00953849?
The interventions under investigation include: Celecoxib (DRUG), Calcitriol (DRUG), Celecoxib plus Calcitriol (DRUG).
Who is sponsoring clinical trial NCT00953849?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00953849 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mouth Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00953849's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia